GGrantIndex
← Leaderboards

Helen C Kales

University Of Michigan At Ann Arbor

$5,891,213
Attributed
$8,600,102
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $836.4K · FY200623
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$8,600,102 · 5
VA$0 · 1

By mechanism

R01$8,229,853 · 4
R21$370,249 · 1
I01$0 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Pharmaceutical Preparations

Research focus

Pharmaceutical PreparationsNursing HomesCaringSeveritiesReportingHealth Care Service UtilizationBehavioral SymptomsAntipsychotic AgentsAggressive BehaviorDementiaAlzheimer&AposDesignPersonsSamplingResponseRandomizedPreventComplexBehavioralCharacteristicsCaregiversFamilyRaceSymptoms

Grant awards (22)

Efficacy of the WeCareAdvisor: An Online Tool to Help Caregivers Manage Behavioral and Psychological Symptoms in Persons with Dementia$726,223
R01 · FY2023 · AG
Efficacy of the WeCareAdvisor: An Online Tool to Help Caregivers Manage Behavioral and Psychological Symptoms in Persons with Dementia$738,480
R01 · FY2022 · AG
Efficacy of the WeCareAdvisor: An Online Tool to Help Caregivers Manage Behavioral and Psychological Symptoms in Persons with Dementia$754,564
R01 · FY2021 · AG
Efficacy of the WeCareAdvisor: An Online Tool to Help Caregivers Manage Behavioral and Psychological Symptoms in Persons with Dementia$769,158
R01 · FY2020 · AG
Efficacy of the WeCareAdvisor: An Online Tool to Help Caregivers Manage Behavioral and Psychological Symptoms in Persons with Dementia$811,633
R01 · FY2019 · AG
Unintended Consequences: The Impact of VA Antipsychotic Reduction Efforts in Dementia$0
I01 · FY2019 · VA · contact PI
Unintended Consequences: The Impact of VA Antipsychotic Reduction Efforts in Dementia$0
I01 · FY2018 · VA · contact PI
Unintended Consequences: The Impact of VA Antipsychotic Reduction Efforts in Dementia$0
I01 · FY2018 · VA · contact PI
An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia$181,081
R01 · FY2015 · NR · contact PI
An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia$522,748
R01 · FY2014 · NR · contact PI
2/2-Personalized Antidepressant Adherence Strategies for Depressed Elders$277,101
R01 · FY2014 · MH · contact PI
An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia$389,246
R01 · FY2013 · NR · contact PI
2/2-Personalized Antidepressant Adherence Strategies for Depressed Elders$299,269
R01 · FY2013 · MH · contact PI
An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia$524,646
R01 · FY2012 · NR · contact PI
2/2-Personalized Antidepressant Adherence Strategies for Depressed Elders$311,739
R01 · FY2012 · MH · contact PI
2/2-Personalized Antidepressant Adherence Strategies for Depressed Elders$311,739
R01 · FY2011 · MH · contact PI
2/2-Personalized Antidepressant Adherence Strategies for Depressed Elders$313,032
R01 · FY2010 · MH · contact PI
Antipsychotics and Mortality in Older Patients$424,983
R01 · FY2009 · MH · contact PI
Antipsychotics and Mortality in Older Patients$412,741
R01 · FY2008 · MH · contact PI
Antipsychotics and Mortality in Older Patients$461,470
R01 · FY2007 · MH · contact PI
Racial Differences in Geriatric Antidepressant Adherence$199,249
R21 · FY2007 · MH · contact PI
Racial Differences in Geriatric Antidepressant Adherence$171,000
R21 · FY2006 · MH · contact PI